NCT01982552
Completed
N/A
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
ConditionsPsoriasis Vulgaris
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Psoriasis Vulgaris
- Sponsor
- LEO Pharma
- Enrollment
- 147
- Locations
- 12
- Primary Endpoint
- Dermatology Life Quality Index (DLQI)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for treatment of plaque psoriasis under real-life conditions.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed and dated informed consent obtained prior to any study related activities
- •Aged 18 years or above
- •Any race or ethnicity
- •Attending a hospital outpatient clinic or the private practice of a board-certified dermatologist, dermatology-certified nurse practitioner or physician assistant trained in dermatology
- •Clinical diagnosis of psoriasis vulgaris involving scalp and/or body amenable to treatment with a maximum of 100 g of topical medication per week.
- •Patients who receive a prescription of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% as per an investigator's clinical judgment and in accordance with the US label, and who have access to the medication
- •Able to communicate with the investigator, read and understand English, and understand and comply with the requirements of the study
Exclusion Criteria
- •Prior treatment with calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension, 0.005%/0.064%.
- •Contraindications or any warnings/precautions according to the US label.
- •Current participation in any other interventional clinical study.
- •Females who are pregnant, breast-feeding, or females of child-bearing potential wishing to become pregnant during the study.
Outcomes
Primary Outcomes
Dermatology Life Quality Index (DLQI)
Time Frame: 8 weeks
Mean change from baseline
Secondary Outcomes
- Visual Analogue Scale for itching(2 and 8 weeks)
- Patient Global Assessment (PGA)(2 and 8 weeks)
- Dermatology Life Quality Index (DLQI)(2 and 8 weeks)
- Treatment Satisfaction Questionnaire for Medication (TSQM)-9(2 and 8 weeks)
Study Sites (12)
Loading locations...
Similar Trials
Completed
N/A
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering SurgeryBreast CancerBreast SurgeryBreast ReconstructionBreast ReductionBreast AugmentationNCT00605670Memorial Sloan Kettering Cancer Center722
Completed
N/A
Quality of Life After Enhanced Recovery Protocol for Colorectal SurgerySurgeryNCT02824783University of Liege41
Completed
N/A
Evaluating Patient and Caregiver Satisfaction with the Informed Consent Process in SurgeryInformed ConsentPatient and Caregiver SatisfactionNCT06746207Maharajgunj Medical Campus384
Active, Not Recruiting
N/A
Patient Satisfaction in Cutaneous SurgerySkin CancerNCT01535963Northwestern University354
Recruiting
N/A
Observational study to evalute patient satisfaction with different oral cannabis productsPatients (cannabis-naïve / cannabis-experienced) with a diagnosed disease for which medical cannabis is indicated in the sense of the Cannabis as Medicine (CAM) Act.DRKS00032743Avextra Pharma GmbH500